Novo Nordisk’s eighth annual integrated report, now online, reports on the company’s very positive financial, social and environmental performance for 2011. Download the Annual Report 2011 at annualreport2011.novonordisk.com.

• Sales increased by 11% (in local currencies) and by 9% in Danish kroner compared to 2010.
• Operating profit increased by 22% (in local currencies) and 18% in Danish kroner compared to 2010.
• Significant clinical development progress was made during the year, including regulatory filing for two ultra-long-acting insulins, Degludec and DegludecPlus. 
• More than 835,000 healthcare providers were trained by Novo Nordisk or Novo Nordisk sponsored programmes, an increase of 123% compared to 2010.
• Diversity in senior management teams increased to 62% at the end of 2011, compared to 54% at the end of 2010.
• CO₂ emissions from production fell by 2% compared to 2010, for an absolute reduction of 56% compared to 2004 levels.

Novo Nordisk’s 2011 Annual Report includes a detailed account of 2011 accomplishments, an outlook for 2012, and an overview of the company’s management approach, corporate strategy and business segments.  It features consolidated financial, social and environmental statements.

The Annual Report 2011 includes updated information for financial and environmental targets.

Novo Nordisk’s integrated reporting

Novo Nordisk manages its business using the Triple Bottom Line principle to ensure that decision-making balances profitability with longer-term societal interests. Material and business-critical information is reported in the Annual Report.  The company reports additional information for specific stakeholder groups at annualreport2011.novonordisk.com. Novo Nordisk values feedback and welcomes questions or comments about its reporting and performance at annualreport@novonordisk.com.

About Novo Nordisk

Novo Nordisk is a global healthcare company with nearly 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs more than 32,000 employees in 75 countries, and markets its products in more than 190 countries. Novo Nordisk's B shares are listed on the NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).

Novo Nordisk strives to conduct its activities in a financially, environmentally and socially responsible way. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today's business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance. In 2012, Novo Nordisk receive top ranking on Corporate Knight’s list of Global 100 Most Sustainable Corporations. Novo Nordisk is listed in the 2010/2011 Dow Jones Sustainability Indices with a gold class rating. For more information, visit novonordisk.com/sustainability.

Novo Nordisk

Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. We believe that a healthy economy, environment and society are fundamental to long-term value creation. This is why we manage our business in accordance with the Triple Bottom Line business principle and consider the financial, environmental and social impact of our business decisions. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today's business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance.

More from Novo Nordisk